Last €87.47 EUR
Change Today +1.06 / 1.23%
Volume 0.0
LAB On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 10:30 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

laboratory crp of amer hldgs (LAB) Snapshot

Open
€86.28
Previous Close
€86.41
Day High
€87.47
Day Low
€86.28
52 Week High
12/22/14 - €87.47
52 Week Low
02/4/14 - €64.45
Market Cap
7.4B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
84.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LABORATORY CRP OF AMER HLDGS (LAB)

laboratory crp of amer hldgs (LAB) Related Businessweek News

No Related Businessweek News Found

laboratory crp of amer hldgs (LAB) Details

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company provides testing services that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases. It also offers specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, women's health, cardiovascular disease, identity, forensics, infectious disease, endocrine sciences, oncology, occupational testing, and pain management. The company provides its services through a sales force to the physicians, hospitals, managed care organizations, governmental agencies, employers, pharmaceutical companies, and other independent clinical laboratories. It operates a national network of 44 primary laboratories and approximately 1,700 patient service centers, as well as branches and STAT laboratories. Laboratory Corporation of America Holdings has collaboration with university, hospital and academic institutions, such as Duke University, The Johns Hopkins University, the University of Minnesota, and Yale University to license and commercialize new diagnostic tests. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

34,000 Employees
Last Reported Date: 02/25/14
Founded in 1971

laboratory crp of amer hldgs (LAB) Top Compensated Officers

Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $587.2K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $371.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $345.3K
Compensation as of Fiscal Year 2013.

laboratory crp of amer hldgs (LAB) Key Developments

Laboratory Corp. of America Holdings(NYSE:LH) dropped from S&P 500 Growth Index

Laboratory Corp. of America Holdings(NYSE:LH) dropped from S&P 500 Growth Index

Covance Inc., Laboratory Corp. of America Holdings - M&A Call

Covance Inc., Laboratory Corp. of America Holdings - M&A Call

Laboratory Corp. of America Holdings Reports Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

Laboratory Corp. of America Holdings reported consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company’s net sales were $1,551.8 million against $1,462.2 million a year ago. Operating income was $241.4 million against $244.6 million a year ago. Earnings before income tax were $219 million against $230 million a year ago. Net earnings attributable to company were $137.2 million or $1.59 per diluted share against $148.3 million or $1.63 per diluted share a year ago. Adjusted operating income was $252.7 million against $248.3 million a year ago. Adjusted EPS excluding amortization was $1.80 against $1.80 a year ago. Net cash provided by operating activities was $175.6 million against $234.2 million a year ago. Capital expenditures were $52.6 million against $52.1 million a year ago. The increase in sales was the result of volume, measured by requisitions, and fold-in acquisitions, which was partially offset by price and mix. The increase in adjusted operating income was due to increased volume and improved productivity, which was partially offset by price, mix, personnel and an increase in bad debt expense. Capital expenditures were essentially unchanged from last year. As a result, free cash flow or cash from operating activities after capital expenditures was $123 million compared to $182 million last year. For the nine months, the company’s net sales were $4,498.9 million against $4,371.3 million a year ago. Operating income was $691.4 million against $775.9 million a year ago. Earnings before income tax were $639.2 million against $721.4 million a year ago. Net earnings attributable to company were $391.6 million or $4.53 per diluted share against $447.5 million or $4.81 per diluted share a year ago. Adjusted operating income was $717 million against $793.7 million a year ago. Adjusted EPS excluding amortization was $5.15 against $5.33 a year ago. Net cash provided by operating activities was $525.3 million against $570 million a year ago. Capital expenditures were $157.2 million against $142.6 million a year ago. The decrease in adjusted operating income was primarily due to the benefit of increased volume being more than offset by price, mix, personnel and bad debt expense. The decline in operating cash flow versus last year was primarily due to lower net earnings. The company expected revenue growth in 2014 of approximately 3.0% over 2013, adjusted EPS of $6.70 to $6.80, operating cash flow of $760 million to $780 million, capital expenditures of $200 million to $205 million and free cash flow of $555 million to $580 million. The lower free cash flow range is reflective of additional working capital needs to support its strong top line growth, as well as investments associated with business process improvement initiative and restructuring activities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LAB:GR €87.47 EUR +1.06

LAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $31.29 USD +1.38
Genomic Health Inc $32.35 USD +1.04
Myriad Genetics Inc $36.12 USD -0.30
QIAGEN NV €19.34 EUR +0.089
Quest Diagnostics Inc $67.54 USD +1.20
View Industry Companies
 

Industry Analysis

LAB

Industry Average

Valuation LAB Industry Range
Price/Earnings 17.8x
Price/Sales 1.5x
Price/Book 3.2x
Price/Cash Flow 14.9x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORY CRP OF AMER HLDGS, please visit www.labcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.